| payload |
{"created_at":"2026-04-04T03:03:53.521 {"created_at":"2026-04-04T03:03:53.521137+00:00","dedupe_key":"signal_enriched:discovery_sec_filing_delta:b8496126dc75f5c9","evidence_event_ids":["evt_0d5c7de1b211"],"signal_type":"discovery_sec_filing_delta","source":"discovery_sec_filings","value":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1649904/0001104659-26-039687.txt","as_of":"2026-04-04T03:03:53.521137+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1649904/0001104659-26-039687.txt","company":"RHYTHM PHARMACEUTICALS, INC.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1649904/0001104659-26-039687.txt","article_chars":2223,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_54d40a80f9c27820","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1649904/0001104659-26-039687.txt","content_type":"text/plain","enriched_at":"2026-04-04T03:28:52.597202+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1649904/0001104659-26-039687.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1649904/0001104659-26-039687.txt","source_event_id":"evt_0d5c7de1b211","source_quality":"high","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"a577975f72c17bb0","kind":"sec_filing","published_at":"20260403","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.9,"dates_mentioned":["2026-04-01","2026-04-03"],"entities":[{"asset_class":"equity","name":"RHYTHM PHARMACEUTICALS, INC.","relevance":"high","symbol":"RYTM","type":"company"}],"event_type":"listing","information_gaps":["No prior state of ownership disclosed for comparison."],"key_facts":["Filing date: April 3, 2026","Form type: 4","Reporting owner: Yann Mazabraud","Transactions include 10,375 shares of common stock and 12,875 restricted stock units."],"numeric_claims":[{"label":"Common Stock Transactions","value":"10,375"},{"label":"Restricted Stock Units","value":"12,875"}],"primary_claim":"Yann Mazabraud reported transactions involving common stock and restricted stock units in RHYTHM PHARMACEUTICALS, INC.","relevance_score":0.8,"sentiment":"neutral","source_quality":"high","summary":"RHYTHM PHARMACEUTICALS, INC. filed a Form 4 on April 3, 2026, disclosing stock transactions by executive Yann Mazabraud.","topics":["SEC Filing","Executive Transactions","Stock Ownership"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 RHYTHM PHARMACEUTICALS, INC. \u00b7 Filed 20260403","ticker":"RYTM","tickers":["RYTM"],"title":"RYTM filed 4","url":"https://www.sec.gov/Archives/edgar/data/1649904/0001104659-26-039687.txt"}}... |